Buprenorphine
bupe · Subutex · Suboxone
What does current UK evidence show?
Current national sources support continued monitoring within the wider opioid and treatment picture; they do not indicate a distinct emerging UK market shift.
Overview
Identity, legal classification, form and pharmacological context
- Drug category
- Opioids · Medicines
- Common names
- bupe, Subutex, Suboxone
- Typical forms
- Sublingual tablets, buccal films and long-acting injectable formulations; patches are also used for pain
- Routes
- Treatment formulations are commonly absorbed under the tongue or inside the cheek, or given by trained staff as a long-acting injection. Swallowing is not the principal intended route for sublingual or buccal products
- UK legal classification
- Class CSchedule 3 medicine under the Misuse of Drugs Regulations 2001.Check government source ↗
- Concise pharmacology
- Buprenorphine is a partial mu-opioid receptor agonist. In appropriate treatment it reduces illicit opioid use and mortality; its formulations have different intended routes.
Main harms
Concise clinical and polydrug picture
Respiratory depression has a ceiling effect relative to full agonists, but serious or fatal oversedation is still possible, especially with alcohol, benzodiazepines or other depressants.
Physical dependence can occur during effective treatment and is not the same as addiction. Constipation and other adverse effects need review, while continuity of treatment helps protect against illicit opioid harm.
Interrupting treatment can cause opioid withdrawal and loss of protection; changes or transfers should be clinically planned.
Benzodiazepines, alcohol, gabapentinoids and other sedatives increase respiratory-depression risk.
Using a formulation by a route for which it was not designed can alter absorption and increase harm; injecting diverted products adds infection and tissue-damage risks.
Current intelligence status
Assessment, confidence and direction
Current national sources support continued monitoring within the wider opioid and treatment picture; they do not indicate a distinct emerging UK market shift.
Reason: Credible but partial sources support a constrained assessment; the direction or reach cannot be generalised across the UK.
Principal source limits: Treatment contact reflects recorded service need and access in England, not population prevalence. Deaths are counted by registration year; 62.7% of the 2025 registrations concern earlier deaths. Substance mentions overlap and do not prove sole causation.
Geography and reference periods are given in each linked source card below. The rating is an editorial evidence judgement, not a probability, clinical risk score or TD priority.The assessment reflects the latest linked evidence and is not a universal severity rating.
Operational implications
Evidence-supported prompts for professional response
Protect access to evidence-based opioid treatment while monitoring diversion, unsafe combinations and continuity of care.
Record substance, sold identity, route, frequency and combinations; review overdose and withdrawal needs.
Prioritise airway and breathing, give naloxone for suspected opioid overdose and continue supportive care.
Triangulate treatment, mortality, testing, hospital and frontline evidence before assigning a local trend.
Related intelligence
Continue into connected platform evidence
Sources & limitations
Direct evidence links, reference periods and status
Adult substance misuse treatment statistics
Published04 Dec 2025Reference periodEngland · 2024–25
Treatment contact reflects recorded service need and access in England, not population prevalence.Deaths related to drug poisoning in England and Wales: 2025 registrations
Published4 Nov 2026Reference period2025 registrations; 2024 occurrences
Deaths are counted by registration year; 62.7% of the 2025 registrations concern earlier deaths. Substance mentions overlap and do not prove sole causation.Oral methadone and buprenorphine recommendations
Published27 Dec 2024Reference periodEngland · opioid substitution treatment
Treatment benefits and individual medicine choice require assessment; death mentions do not identify prescribing circumstances.